Top ▲
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 658 | 9q34.11 | ENG | endoglin | |
Mouse | 1 | 653 | 2 22.09 cM | Eng | endoglin | |
Rat | 1 | 650 | 3 | Eng | endoglin | |
Gene and Protein Information Comments | ||||||
Three transcript variants are identified for the human ENG gene, producing three protein isoforms. The table shows details for the longest isoform (L-endoglin). Isoform 2 (S-endoglin, 625aa) has a shorter and distinct C-terminus compared to isoform 1 and isoform 3 (476aa) has a shorter N-terminus compared to isoform 1. Similarly for the mouse, three transcript variants and protein isoforms have been reported. |
Previous and Unofficial Names ![]() |
CD105 | END | HHT1 | Osler-Rendu-Weber syndrome 1 (ORW1) |
Database Links ![]() |
|
Alphafold | P17813 (Hs), Q63961 (Mm) |
ChEMBL Target | CHEMBL3712885 (Hs) |
Ensembl Gene | ENSG00000106991 (Hs), ENSMUSG00000026814 (Mm), ENSRNOG00000050190 (Rn) |
Entrez Gene | 2022 (Hs), 13805 (Mm), 497010 (Rn) |
Human Protein Atlas | ENSG00000106991 (Hs) |
KEGG Gene | hsa:2022 (Hs), mmu:13805 (Mm), rno:497010 (Rn) |
OMIM | 131195 (Hs) |
Pharos | P17813 (Hs) |
RefSeq Nucleotide | NM_001114753 (Hs), NM_001278138 (Hs), NM_000118 (Hs), NM_007932 (Mm), NM_001146348 (Mm), NP_001139820 (Mm), NM_001146350 (Mm), NM_001010968 (Rn) |
RefSeq Protein | NP_000109 (Hs), NP_001108225 (Hs), NP_001265067 (Hs), NP_001139822 (Mm), NP_031958 (Mm), NP_001010968 (Rn) |
UniProtKB | P17813 (Hs), Q63961 (Mm) |
Wikipedia | ENG (Hs) |
Download all structure-activity data for this target as a CSV file
Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Clinically-Relevant Mutations and Pathophysiology ![]() |
||||||||||||||
|
General Comments |
Endoglin is a type I membrane glycoprotein. It is part of the TGFβ receptor complex. As endoglin appears to play an important role in tumour neo-angiogenesis, growth and metastasis, it is being investigated as a novel oncology drug target. For example, carotuximab is an anti-endoglin mAb in clinical development. |
1. Theuer C, Vasquez M. (2012) Endoglin antibodies. Patent number: US8221753 B2. Assignee: Tracon Pharmaceuticals, Inc.. Priority date: 30/09/2009. Publication date: 17/07/2012.
CD molecules: endoglin (CD105). Last modified on 20/03/2017. Accessed on 25/04/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2895.